While the NRG-GY004 phase III trial assessing olaparib versus olaparib and cediranib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients did not show any difference between treatment arms in the whole population, subgroup analyses suggested the efficacy of the combination therapy in BRCA1/2-mutated patients. The gene discussed is BRCA1; the disease is ovarian cancer.